Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:23:13.056Z.
Calculation as of: 2026-10-06T19:23:13.056Z.
Quote observation: 2026-10-06T19:07:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fae3dac89f6aae568c3e1e6131ec6a0b9ed594063ed7dd46d2bf25dadf8b5230
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
OKYO Pharma Limited
Market Cap
$56.02M
Price/OCF Ratio
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO |
|---|---|---|
| OKYO Pharma Limited (OKYO) | $56.02M | N/A |
| Talphera, Inc. (TLPH)vs › | $57.35M | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $57.93M | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $58.21M | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $53.58M | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.54M | N/A |
| Spectral AI, Inc. (MDAI)vs › | $53.31M | N/A |
| Aldeyra The (ALDX)vs › | $53.30M | N/A |
| ImageneBio Inc (IMA)vs › | $53.24M | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $59.00M | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
